Colorectal cancer (CRC) is the third leading cause of cancer death in the Western world, accounting for approximately 140,000 new cases and more than 51,000 deaths in 2010 in the United States. In Kuwait, CRC is the first most-diagnosed neoplasm among males and overall, the second leading cause of death from cancer. The 5-year survival rate in 2002-2004 was 61% for men and 62% for women. Even after complete resection of the colorectal tumor, distant metastases have been noted to develop in 10%-15% of patients. Of all metastases, those to the liver were found in 20%-30% of cases, and to the lung, in 10%-20%; brain metastases are quite rare. The percentage of CRC patients developing brain metastases during the course of their disease is reported to range from 2% to 12%, but the effect of such metastases on the patient's prognosis is significant. With the advent of new targeted therapies and the resulting improvements in outcome for CRC patients, the management policy for brain metastases has changed. Regardless of the therapy used to address brain metastases, reported median survival ranges from 2.8 months to 6 months. We report a case of brain metastasis in a patient of primary colorectal adenocarcinoma. He was evaluated for convulsion, CT findings showed brain metastasis.

Download full-text PDF

Source

Publication Analysis

Top Keywords

brain metastases
16
brain metastasis
12
colorectal adenocarcinoma
8
crc patients
8
brain
7
metastases
7
colorectal
4
metastasis colorectal
4
adenocarcinoma case
4
case report
4

Similar Publications

Regulation of metastatic organotropism.

Trends Cancer

December 2024

Herbert Irving Comprehensive Cancer Center, New York, NY, 10032, USA; Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, 10032, USA; Division of Digestive and Liver Diseases, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY 10032, USA. Electronic address:

Metastasis is responsible for most cancer-related deaths. Different cancers have their own preferential sites of metastases, a phenomenon termed metastatic organotropism. The mechanisms underlying organotropism are multifactorial and include the generation of a pre-metastatic niche (PMN), metastatic homing, colonization, dormancy, and metastatic outgrowth.

View Article and Find Full Text PDF

Biomimetic membrane-coated nanoparticles specially permeate the inflammatory blood-brain barrier to deliver plasmin therapy for brain metastases.

J Control Release

December 2024

Jiangsu Key Laboratory of Neuropsychiatric Diseases Research, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China; Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Soochow University, Suzhou 215123, China. Electronic address:

Many brain-targeting drug delivery strategies have been reported to permeate the blood-brain barrier (BBB) via hijacking receptor-mediated transport. However, these receptor-based strategies could mediate whole-brain BBB crossing due to the wide intracranial expression of target receptors and lead to unwanted accumulation and side effects on healthy brain tissues. Inspired by brain metastatic processes and the selectivity of brain metastatic cancer cells for the inflammatory BBB, a biomimetic nanoparticle was developed by coating drug-loaded core with the inflammatory BBB-seeking erythrocyte-brain metastatic hybrid membrane, which can resist homotypic aggregation and specially bind and permeate the inflammatory BBB for specific drug delivery.

View Article and Find Full Text PDF

Introduction: Tumorous growths in the sellar region pose significant clinical challenges due to their proximity to critical visual structures such as the optic chiasm and optic nerves. Given their proximity to the optic system, these tumors are often diagnosed due to a progressive decrease in visual acuity. Thus, surgical intervention is crucial to prevent irreversible damage, as timely decompression can halt the progression of edema and subsequent optic atrophy.

View Article and Find Full Text PDF

Histologic transformation from non-small cell to small cell lung cancer (SCLC) is a resistance mechanism to immune checkpoint inhibitors. We report herein a case of lung adenocarcinoma who developed liver and brain metastases during adjuvant atezolizumab therapy. The patient underwent a craniotomy to resect a brain metastasis, which was pathologically diagnosed as SCLC.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!